326 related articles for article (PubMed ID: 20231678)
21. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
Kubota K; Kunitoh H; Seto T; Shimada N; Tsuboi M; Ohhira T; Okamoto H; Masuda N; Maruyama R; Shibuya M; Watanabe K
Lung Cancer; 2020 Mar; 141():32-36. PubMed ID: 31931444
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Davies AM; Chansky K; Lara PN; Gumerlock PH; Crowley J; Albain KS; Vogel SJ; Gandara DR;
J Thorac Oncol; 2009 Jan; 4(1):87-92. PubMed ID: 19096312
[TBL] [Abstract][Full Text] [Related]
24. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
Custodio Carretero AB; García Sáenz JA; González Larriba JL; Bobokova J; Calles Blanco A; Hernando Trancho F; García Paredes B; Rodríguez Lajusticia L; Díaz-Rubio García E
Clin Transl Oncol; 2008 Sep; 10(9):560-71. PubMed ID: 18796373
[TBL] [Abstract][Full Text] [Related]
27. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
Choy H; Devore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; Johnson DH
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):931-7. PubMed ID: 10863062
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
Schilder RJ; Goldberg M; Millenson MM; Movsas B; Rogatko A; Rogers B; Langer CJ
Lung Cancer; 2000 Jan; 27(1):37-45. PubMed ID: 10672782
[TBL] [Abstract][Full Text] [Related]
31. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
Hoang T; Dahlberg SE; Sandler AB; Brahmer JR; Schiller JH; Johnson DH
J Thorac Oncol; 2012 Sep; 7(9):1361-8. PubMed ID: 22843087
[TBL] [Abstract][Full Text] [Related]
32. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
Altorki NK; Keresztes RS; Port JL; Libby DM; Korst RJ; Flieder DB; Ferrara CA; Yankelevitz DF; Subbaramaiah K; Pasmantier MW; Dannenberg AJ
J Clin Oncol; 2003 Jul; 21(14):2645-50. PubMed ID: 12860939
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
Borghaei H; Langer CJ; Millenson M; Ruth KJ; Litwin S; Tuttle H; Seldomridge JS; Rovito M; Mintzer D; Cohen R; Treat J
J Thorac Oncol; 2008 Nov; 3(11):1286-92. PubMed ID: 18978564
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
[TBL] [Abstract][Full Text] [Related]
35. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team.
Pisters KM; Ginsberg RJ; Giroux DJ; Putnam JB; Kris MG; Johnson DH; Roberts JR; Mault J; Crowley JJ; Bunn PA
J Thorac Cardiovasc Surg; 2000 Mar; 119(3):429-39. PubMed ID: 10694600
[TBL] [Abstract][Full Text] [Related]
36. A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Banna GL; Lipari H; Nicolosi M; Basile A; Fraggetta F; Vaglica M; Marletta F; Urso OE; Ippolito M; Terminella A; Saita S
Med Oncol; 2013 Jun; 30(2):533. PubMed ID: 23512427
[TBL] [Abstract][Full Text] [Related]
37. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Herbst RS; Kelly K; Chansky K; Mack PC; Franklin WA; Hirsch FR; Atkins JN; Dakhil SR; Albain KS; Kim ES; Redman M; Crowley JJ; Gandara DR
J Clin Oncol; 2010 Nov; 28(31):4747-54. PubMed ID: 20921467
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
[TBL] [Abstract][Full Text] [Related]
39. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test.
Kolek V; Grygarkova I; Hajduch M; Klein J; Cwiertka K; Neoral C; Langova K; Mihal V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):259-66. PubMed ID: 19219217
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.
Scagliotti GV; Pastorino U; Vansteenkiste JF; Spaggiari L; Facciolo F; Orlowski TM; Maiorino L; Hetzel M; Leschinger M; Visseren-Grul C; Torri V
J Clin Oncol; 2012 Jan; 30(2):172-8. PubMed ID: 22124104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]